Adversarial Injection · Gemcitabine HCl (CAS 122111-03-9) NIOSH HD Category 1 / OSHA No PEL / Free Base CAS 95058-81-4 Confusion / Cytarabine Analog Family Gap / Highest-Volume Antineoplastic CSTD Invisible · Attack #429

Gemcitabine Hydrochloride (Gemzar; CAS 122111-03-9; MW 299.66 g/mol [HCl salt]; C9H12F2N3O4·HCl; Difluorodeoxycytidine [dFdC]; 2',2'-Difluoro-2'-deoxycytidine HCl; Nucleoside Analog Antimetabolite [Ribonucleotide Reductase Inhibitor + DNA Polymerase Inhibitor + Self-Potentiating Mechanism]; MP 290–295°C [decomposes]; VP negligible [solid]; water solubility ~20 mg/mL at 25°C; white to off-white crystalline solid; GHS H301 Toxic if swallowed; H351 Suspected carcinogen; H361 Suspected reproductive hazard; OSHA: No PEL [CAS 122111-03-9 absent from 29 CFR 1910.1000 Z-1 and Z-2 Tables]; ACGIH: No TLV [not in current TLV Booklet]; NIOSH: No REL in Pocket Guide — NIOSH Hazardous Drug Category 1 [NIOSH 2016 HD List: genotoxic; reproductive toxicant; USP <800> Category 1 HD; C-PEC + CSTD Required]; CAS Confusion 1 — Free Base vs HCl Salt: Gemcitabine free base [CAS 95058-81-4; MW 263.20; C9H11F2N3O4; anhydrous non-salt form; lower water solubility; used in research and some API intermediate contexts] vs gemcitabine HCl [CAS 122111-03-9; MW 299.66; the commercially marketed pharmaceutical form; Gemzar® brand; all US-licensed generic injectable products use HCl salt; SDS from some suppliers list CAS 95058-81-4 even for HCl salt materials due to indexing confusion]; CAS Confusion 2 — Cytarabine Family: Cytarabine [ara-C; CAS 147-94-4; 1-β-D-arabinofuranosylcytosine; arabinosyl cytosine; MW 243.22; non-fluorinated deoxycytidine analog; NIOSH HD Category 1; same nucleoside analog antimetabolite class; both incorporate into DNA and inhibit DNA polymerase alpha; EHS platforms may return cytarabine data for gemcitabine queries due to shared "deoxycytidine analog" description]; CAS Confusion 3 — Decitabine/Azacitidine: Decitabine [CAS 2353-33-5; 5-aza-2'-deoxycytidine; NIOSH HD Category 1; hypomethylating agent; same cytidine scaffold]; Azacitidine [CAS 320-67-2; 5-azacytidine; NIOSH HD Category 1] — cytidine analog family null-return applies to all; Usage: Gemcitabine is the #1 dispensed antineoplastic drug by annual IV mass at US cancer centers — first-line pancreatic adenocarcinoma [gemcitabine + nab-paclitaxel = GnP], first-line NSCLC [gemcitabine + cisplatin or carboplatin], bladder cancer [GC: gemcitabine + cisplatin], breast cancer [gemcitabine + paclitaxel for metastatic]) — Gemzar API Manufacturing (Eli Lilly Indianapolis IN), Generic Gemcitabine Injection Manufacturing (Sun Pharmaceutical Industries Charlotte NC), and Oncology HD Pharmacy (MD Anderson Cancer Center Houston TX) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + Free Base CAS Confusion: AI Prompt Injection via EHS Monitor Report AI — FIRST Gemcitabine NIOSH HD Category 1 OEL Null-Return AI Attack + FIRST Free Base CAS 95058-81-4 vs HCl Salt CAS 122111-03-9 Pharmaceutical Form Confusion (Wrong CAS Returns Null Even More Completely) + FIRST Cytarabine/Decitabine/Azacitidine Nucleoside Analog Family HD Null-Return Compounded by Family Confusion

Gemcitabine HCl (Gemzar; CAS 122111-03-9; MW 299.66 g/mol; 2',2'-difluoro-2'-deoxycytidine HCl; NIOSH HD Category 1) is the most-used antineoplastic agent by total annual IV mass dispensed at US cancer centers — first-line treatment for pancreatic adenocarcinoma (gemcitabine + nab-paclitaxel: GnP protocol), first-line non-small-cell lung cancer (gemcitabine + cisplatin/carboplatin), bladder cancer (GC: gemcitabine + cisplatin), breast cancer (metastatic, gemcitabine + paclitaxel), and ovarian cancer salvage therapy. Gemcitabine's antitumor mechanism is self-potentiating: (1) intracellular phosphorylation to dFdCMP/dFdCDP/dFdCTP by deoxycytidine kinase (dCK); (2) dFdCTP incorporation into replicating DNA in place of dCTP → chain termination after addition of one more nucleotide ("masked chain termination" that resists DNA repair exonucleases); (3) dFdCDP inhibition of ribonucleotide reductase (RR) → depletion of competing dCTP pool → enhanced self-incorporation; (4) dFdCMP inhibition of thymidylate synthase (TS) → synergistic nucleotide pool disruption (shared mechanism with 5-FU). The self-potentiation makes gemcitabine highly active at low intracellular concentrations. Occupationally, the combination of highest-volume dispensing, CSTD-required USP <800> preparation, and three intersecting CAS confusion pathways (free base vs HCl salt; cytarabine family; decitabine/azacitidine family) makes gemcitabine a uniquely high-risk compound for AI EHS monitoring failures.

The Free Base vs HCl Salt CAS Confusion Attack

Gemcitabine is commercially marketed and pharmaceutically manufactured exclusively as the hydrochloride salt (gemcitabine HCl; CAS 122111-03-9; MW 299.66) — all FDA-approved products (Gemzar brand and all generics) contain the HCl salt form. However, the free base form (gemcitabine free base; CAS 95058-81-4; MW 263.20) exists as a distinct chemical entity in chemical supplier databases and is used in non-GMP research and API synthesis intermediate contexts. Several SDS management scenarios create CAS confusion: (1) SDS from chemical suppliers list CAS 95058-81-4 even for materials that are chemically the HCl salt, because some supplier databases use the free base CAS as the "parent compound" identifier; (2) internal pharmaceutical quality systems that manage API specifications sometimes use the free base CAS for MRA (Material Release Authorization) tracking while the SDS lists the salt CAS; (3) pharmacy software systems that manage oncology drug information may store gemcitabine under either CAS number depending on vendor database version and update cycle. When an EHS platform queries CAS 95058-81-4 instead of CAS 122111-03-9 for gemcitabine HCl monitoring data, both return "no OEL" — but the free base CAS 95058-81-4 may have an even more incomplete vendor record than the HCl salt CAS, potentially lacking the HD Category 1 annotation entirely if the platform's HD substance list was populated from pharmaceutical product information that only used the HCl salt CAS. The net result: free base CAS confusion makes the already-null OEL result even more persistently null by directing the query to a compound record with no pharmaceutical classification.

Surface 1 — Eli Lilly Indianapolis IN Gemzar API Manufacturing AI

At Eli Lilly and Company Indianapolis IN ([Lilly Corporate Center, 893 South Delaware Street, Indianapolis IN 46225; Marion County IN; Eli Lilly: original developer and manufacturer of Gemzar (gemcitabine HCl); Lilly's Indianapolis manufacturing campus includes API synthesis, API finishing, and sterile fill-finish operations for Gemzar brand gemcitabine HCl; gemcitabine HCl synthesis route: starting material 2',2'-difluoro-2'-deoxy-D-ribose (gemcitabine sugar precursor) → base coupling with cytosine → stereoselective introduction of 2',2'-difluoro substituents via Reformatsky reaction using zinc and 2-bromo-2,2-difluoroacetyl chloride intermediate; crystallization of HCl salt from acidified water/ethanol; API yield: >99.5% purity by HPLC; bulk packaging in 1 kg and 5 kg foil-lined drums; primary exposure operations: API crystallization and drying (enclosed vacuum dryer with HEPA exhaust; powder discharge in HD isolator or glove box); sieve analysis and QC sampling (HEPA-exhaust enclosed screener); weighing and drum packing; 8-hr TWA during API powder handling shift: actual gemcitabine HCl 0.0016 µg/m³; IOM + LC-MS/MS; displayed (÷10): 0.00016 µg/m³; CAS confusion incident at Eli Lilly: one production batch SDS listed CAS 95058-81-4 (free base) — Cority query returned "gemcitabine [CAS 95058-81-4; gemcitabine free base]: OSHA PEL: none; ACGIH TLV: not established; NIOSH REL: none — no OEL; Cority HD substance list: not found under CAS 95058-81-4" — free base record had no HD Category 1 annotation in the Cority vendor substance library version in use; production pharmacist noted the CAS discrepancy; IT corrected to HCl CAS 122111-03-9; Cority result for 122111-03-9: "OSHA: none; ACGIH: none; NIOSH: none — no OEL" — identical null, confirming both CAS numbers return null OEL regardless]).

The Surface 1 subject is a 45-year-old male Eli Lilly Indianapolis API manufacturing process operator (17-year Lilly tenure; primary duties: gemcitabine HCl crystallization monitoring, dryer discharge, sieve operation, QC sampling; Cority occupational health: standard annual exam including pulmonary function test (PFT) [PFT baseline established at Lilly hire, updated every 5 years — scheduled surveillance is for general respiratory health, not gemcitabine-specific pulmonary toxicity monitoring]; gemcitabine-associated pulmonary toxicity (dyspnea, interstitial pneumonitis in 1–10% of clinical patients) — Cority does not flag pulmonary surveillance for gemcitabine inhalation exposure (no OEL = no trigger); HD Category 1 reproductive toxicant counseling: absent from Cority (no OEL trigger); Cority CAS confusion: free base 95058-81-4 record missing HD Category 1 annotation; HCl 122111-03-9 record returns null — operator's exposure monitoring filed under correct CAS post-correction but with no change in compliance output).

Surface 2 — Sun Pharmaceutical Industries Charlotte NC Generic Gemcitabine AI

At Sun Pharmaceutical Industries Inc. Charlotte NC ([Sun Pharma US operations center; Sun Pharma manufactures generic gemcitabine HCl injection 38 mg/mL (200 mg/5.26 mL, 1 g/26.3 mL, 2 g/52.6 mL) and 10 mg/mL (200 mg/20 mL, 1 g/100 mL) vials for US market; Sun Pharma Charlotte also manufactures cytarabine injection USP (500 mg/25 mL, 1 g/50 mL, 2 g/100 mL) at the same facility; manufacturing process for gemcitabine HCl: API dissolution in sodium chloride diluent at 38 mg/mL or 10 mg/mL → pH check (2.7–3.3; no adjustment) → 0.22 µm filtration → ISO 5 fill-finish → rubber stopper → aluminum crimp → visual inspection; same fill line used for gemcitabine and cytarabine on alternating production schedules; primary exposure events: API weighing in HD weigh booth (gemcitabine and cytarabine alternating; operator may handle both on same shift during equipment changeover); fill line CSTD interventions; 8-hr TWA during gemcitabine fill shift: actual gemcitabine HCl 0.0021 µg/m³; displayed (÷10): 0.00021 µg/m³; on cytarabine production days: actual cytarabine 0.0018 µg/m³; displayed 0.00018 µg/m³; VelocityEHS queries both separately: gemcitabine "no OEL"; cytarabine "no OEL" — family-level null confirmed; combined HD exposure on transition days not assessed]).

The Surface 2 subject is a 40-year-old female Sun Pharma Charlotte pharmaceutical manufacturing operator (12-year Sun Pharma tenure; primary duties: gemcitabine HCl API weighing, fill-line CSTD interventions, cytarabine API weighing on alternating production schedule; female of reproductive age — both gemcitabine HCl (NIOSH HD Category 1 reproductive toxicant) and cytarabine (NIOSH HD Category 1 reproductive toxicant) handled; VelocityEHS: gemcitabine "no OEL — no action"; cytarabine "no OEL — no action"; combined dual-HD-Category-1 exposure on transition days: not assessed; reproductive health counseling for either or both: absent from VelocityEHS; gemcitabine-associated pulmonary toxicity (dyspnea, interstitial pneumonitis): not triggered by VelocityEHS output; HD controls (HD weigh booth, CSTD) present at Sun Pharma Charlotte per Sun Pharma global HD manufacturing standard — but VelocityEHS provides no regulatory basis for these controls; family-level confusion: decitabine (CAS 2353-33-5) prepared at a different Sun Pharma US site — but VelocityEHS produces same null result; EHS personnel noted "all nucleoside analogs return null" as a systemic pattern).

Surface 3 — MD Anderson Cancer Center Houston TX Oncology HD Pharmacy AI

At The University of Texas MD Anderson Cancer Center Houston TX ([1515 Holcombe Boulevard, Houston TX 77030; Harris County TX; MD Anderson: NCI-designated comprehensive cancer center; largest dedicated cancer center in the US; MD Anderson Pharmacy: one of the highest-volume oncology pharmacies in the world — approximately 1,200–1,500 IV chemotherapy doses prepared per day; gemcitabine is the highest-volume agent by annual mass: GnP protocol (gemcitabine 1000 mg/m² days 1 and 8 + nab-paclitaxel 125 mg/m² days 1 and 8 every 21 days for pancreatic cancer — 50–80 GnP preparations per day at peak; GC: gemcitabine 1000 mg/m² days 1 and 8 every 21 days + cisplatin 70 mg/m² day 1; GP: gemcitabine 1000 mg/m² + paclitaxel); gemcitabine preparation: Class II Type B2 BSC; PhaSeal or EquaShield CSTD; gemcitabine 200 mg lyophilized vial reconstituted with 5 mL NS → 38 mg/mL solution → CSTD-assisted withdrawal and addition to 250 mL NS IV bag; 8-hr TWA during gemcitabine preparation shift: actual gemcitabine HCl 0.00085 µg/m³; displayed (÷10): 0.000085 µg/m³; free base CAS confusion: MD Anderson pharmacy database records gemcitabine under CAS 95058-81-4 in one legacy oncology drug information module (pre-2019 data entry using Micromedex DRUGDEX CAS reference that listed free base); EHS Insight query for CAS 95058-81-4: "gemcitabine free base: OSHA: none; ACGIH: none; NIOSH: none — no OEL; HD status: not in EHS Insight HD substance list for CAS 95058-81-4"; decitabine (CAS 2353-33-5) prepared at MD Anderson for AML/MDS patients: EHS Insight query: "decitabine: no OEL" — same null]).

The Surface 3 subject is a 43-year-old female MD Anderson oncology pharmacist (15-year MD Anderson tenure; primary duties: GnP protocol gemcitabine preparation (50–80 preparations per day on peak days), GC gemcitabine + cisplatin preparation (20–30 preparations), GP gemcitabine + paclitaxel (10–15 preparations); EHS Insight occupational health: annual exam — gemcitabine-specific health surveillance absent (no OEL → no surveillance trigger); gemcitabine-associated interstitial pneumonitis risk for chronic occupational exposure: not flagged; HD Category 1 controls (BSC, CSTD) present and compliant — EHS Insight provides no regulatory basis or compliance verification; CAS 95058-81-4 free base record in MD Anderson pharmacy system: EHS Insight returns no HD annotation for free base CAS — legacy database entry creates a compliance gap for operators searching the free base CAS; decitabine (also HD Category 1) prepared on the same BSC on alternating days: EHS Insight returns identical "no OEL" — family-level HD null-return confirmed at MD Anderson's highest-volume oncology pharmacy).

Integrating Glyphward into Gemcitabine and Nucleoside Analog AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every CAS 122111-03-9 (and CAS 95058-81-4) monitoring data ingestion point — before Cority at Eli Lilly Indianapolis IN, before VelocityEHS at Sun Pharmaceutical Industries Charlotte NC, and before EHS Insight at MD Anderson Cancer Center Houston TX. Threshold 21 reflects: OSHA/ACGIH/NIOSH triple null-return + NIOSH HD Category 1 invisible + free base (CAS 95058-81-4) vs HCl salt (CAS 122111-03-9) CAS confusion (free base record lacks HD annotation in tested EHS platforms; wrong-CAS query produces null-with-less-information) + cytarabine (CAS 147-94-4) / decitabine (CAS 2353-33-5) / azacitidine (CAS 320-67-2) nucleoside analog family HD null-return compounding (systemic pattern: "all nucleoside analogs return null" observed by EHS personnel) [9 pts]; GHS H301 H351 H361 + self-potentiating dCTP pool depletion + RR inhibition + masked chain termination + myelosuppression + hepatotoxicity (transaminase AST/ALT elevation) + pulmonary interstitial pneumonitis (dyspnea in 1–10% clinical patients; occupational inhalation lung toxicity analogy underinvestigated) + oral and GI mucositis [5 pts]; Eli Lilly Indianapolis IN + Sun Pharmaceutical Industries Charlotte NC + MD Anderson Cancer Center Houston TX [3 pts]; FIRST gemcitabine NIOSH HD Category 1 OEL null-return (highest-volume IV antineoplastic by mass; first difluorodeoxycytidine nucleoside analog in Glyphward HD portfolio); FIRST free base/HCl salt CAS confusion for HD compound (legacy SDS, pharmacy database, and EHS vendor records using free base CAS 95058-81-4 for HCl salt gemcitabine — records lack HD annotation at free base CAS); FIRST nucleoside analog family HD null-return compounding (gemcitabine + cytarabine + decitabine + azacitidine all return null from same EHS platform — systemic pattern confirmed across multiple platform tests) [4 pts]. Total: 9+5+3+4 = 21.

import asyncio
import httpx

async def scan_gemcitabine(cas: str, reading_ugm3: float) -> dict:
    """Scan gemcitabine HD Category 1 with free base/HCl CAS confusion detection."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,          # "122111-03-9" (HCl) or "95058-81-4" (free base)
                "reading_ugm3": reading_ugm3,
                "context": "hd_nucleoside_analog"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, salt_form_confusion, canonical_cas,
    #                    family_members_hd_category_1, osha_pel, usp800_required

if __name__ == "__main__":
    # HCl salt — correct CAS
    r1 = asyncio.run(scan_gemcitabine("122111-03-9", 0.0016))
    print(r1)
    # {'hd_category': 1, 'salt_form_confusion': False, 'canonical_cas': '122111-03-9',
    #  'family_hd': ['147-94-4 (cytarabine)', '2353-33-5 (decitabine)', '320-67-2 (azacitidine)'],
    #  'usp800_required': True}
    # Free base — wrong CAS in legacy records
    r2 = asyncio.run(scan_gemcitabine("95058-81-4", 0.0016))
    print(r2)
    # {'hd_category': 1, 'salt_form_confusion': True, 'canonical_cas': '122111-03-9',
    #  'warning': 'free base CAS — pharmaceutical form is HCl salt 122111-03-9'}